Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy.

Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy.
Trends Mol Med. 2020 Oct 19;:
Authors: Cohen J, DeSimone A, Lek M, Lek A
Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common types of muscular dystrophy, affecting roughly one in 8000 individuals. The complex underlying genetics and poor mechanistic understanding has caused a bottleneck in therapeutic development. Until the discovery of DUX4 and its causal role in FSHD, most trials were untargeted with limited results. Emerging approaches can learn from these early trials to increase their chance of success. Here, we explore the evolution of FSHD clinical trials from nonspecific anabolic or anti-inflammatory/oxidant strategies to cutting-edge molecular therapies targeting DUX4, and we discuss the importance of clinical outcome measures. With combined advances across multiple facets of FSHD research, the field is now poised to accelerate the process of therapeutic discovery and testing.
PMID: 33092966 [PubMed - as supplied by publisher]

Source: Trends in Molecular Medicine - October 19, 2020 Category: Molecular Biology Authors: Cohen J, DeSimone A, Lek M, Lek A Tags: Trends Mol Med Source Type: research